AI-Designed vaccine takes on deadly brain cancer in first human trial

This early-phase trial tests a personalized vaccine called Tamavaq NeoVaccine in 29 adults with newly diagnosed glioma, a type of brain cancer. The vaccine is custom-made for each patient using AI and quantum mechanics to target unique cancer markers. The main goal is to check if the vaccine is safe and to monitor side effects like fever, headache, and injection site reactions. This study does not aim to cure the disease but to control it by boosting the immune system's ability to attack the tumor.